ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Adrenoleukodystrophy Drugs Market Research Report 2024
Published Date: February 2024
|
Report Code: QYRE-Auto-28Y8829
Home | Market Reports | Health| Health Conditions| Genetic Disorders
Global Adrenoleukodystrophy Drugs Market Outlook 2022
BUY CHAPTERS

Global Adrenoleukodystrophy Drugs Market Research Report 2024

Code: QYRE-Auto-28Y8829
Report
February 2024
Pages:80
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
bluebird bio Inc
NeuroVia, Inc.
Orpheris, Inc.
Minoryx
MedDay Pharmaceuticals

Adrenoleukodystrophy Drugs Market Size

The global Adrenoleukodystrophy Drugs market was valued at US$ 337.8 million in 2023 and is anticipated to reach US$ 960 million by 2030, witnessing a CAGR of 15.9% during the forecast period 2024-2030.

Adrenoleukodystrophy Drugs Market

Adrenoleukodystrophy Drugs Market

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.
By region, North America has the highest share of revenue, exceeding 60 percent in 2019.
This report aims to provide a comprehensive presentation of the global market for Adrenoleukodystrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adrenoleukodystrophy Drugs.

Report Scope

The Adrenoleukodystrophy Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Adrenoleukodystrophy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adrenoleukodystrophy Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Adrenoleukodystrophy Drugs Market Report

Report Metric Details
Report Name Adrenoleukodystrophy Drugs Market
Accounted market size in 2023 US$ 337.8 million
Forecasted market size in 2030 US$ 960 million
CAGR 15.9%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Hormone Replacement
  • Transplant
  • Others
Segment by Application
  • Childhood Cerebral ALD
  • Adrenomyeloneuropathy (AMN)
  • Addison-only
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bluebird Bio Inc, NeuroVia, Inc., Orpheris, Inc., Minoryx, MedDay Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Adrenoleukodystrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Adrenoleukodystrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Adrenoleukodystrophy Drugs Market growing?

Ans: The Adrenoleukodystrophy Drugs Market witnessing a CAGR of 15.9% during the forecast period 2024-2030.

What is the Adrenoleukodystrophy Drugs Market size in 2030?

Ans: The Adrenoleukodystrophy Drugs Market size in 2030 will be US$ 960 million.

Who are the main players in the Adrenoleukodystrophy Drugs Market report?

Ans: The main players in the Adrenoleukodystrophy Drugs Market are Bluebird Bio Inc, NeuroVia, Inc., Orpheris, Inc., Minoryx, MedDay Pharmaceuticals

What are the Application segmentation covered in the Adrenoleukodystrophy Drugs Market report?

Ans: The Applications covered in the Adrenoleukodystrophy Drugs Market report are Childhood Cerebral ALD, Adrenomyeloneuropathy (AMN), Addison-only, Others

What are the Type segmentation covered in the Adrenoleukodystrophy Drugs Market report?

Ans: The Types covered in the Adrenoleukodystrophy Drugs Market report are Hormone Replacement, Transplant, Others

1 Adrenoleukodystrophy Drugs Market Overview
1.1 Product Overview and Scope of Adrenoleukodystrophy Drugs
1.2 Adrenoleukodystrophy Drugs Segment by Type
1.2.1 Global Adrenoleukodystrophy Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Hormone Replacement
1.2.3 Transplant
1.2.4 Others
1.3 Adrenoleukodystrophy Drugs Segment by Application
1.3.1 Global Adrenoleukodystrophy Drugs Market Value by Application: (2024-2030)
1.3.2 Childhood Cerebral ALD
1.3.3 Adrenomyeloneuropathy (AMN)
1.3.4 Addison-only
1.3.5 Others
1.4 Global Adrenoleukodystrophy Drugs Market Size Estimates and Forecasts
1.4.1 Global Adrenoleukodystrophy Drugs Revenue 2019-2030
1.4.2 Global Adrenoleukodystrophy Drugs Sales 2019-2030
1.4.3 Global Adrenoleukodystrophy Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Adrenoleukodystrophy Drugs Market Competition by Manufacturers
2.1 Global Adrenoleukodystrophy Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Adrenoleukodystrophy Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Adrenoleukodystrophy Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Adrenoleukodystrophy Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adrenoleukodystrophy Drugs, Product Type & Application
2.7 Adrenoleukodystrophy Drugs Market Competitive Situation and Trends
2.7.1 Adrenoleukodystrophy Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Adrenoleukodystrophy Drugs Players Market Share by Revenue
2.7.3 Global Adrenoleukodystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Adrenoleukodystrophy Drugs Retrospective Market Scenario by Region
3.1 Global Adrenoleukodystrophy Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Adrenoleukodystrophy Drugs Global Adrenoleukodystrophy Drugs Sales by Region: 2019-2030
3.2.1 Global Adrenoleukodystrophy Drugs Sales by Region: 2019-2024
3.2.2 Global Adrenoleukodystrophy Drugs Sales by Region: 2025-2030
3.3 Global Adrenoleukodystrophy Drugs Global Adrenoleukodystrophy Drugs Revenue by Region: 2019-2030
3.3.1 Global Adrenoleukodystrophy Drugs Revenue by Region: 2019-2024
3.3.2 Global Adrenoleukodystrophy Drugs Revenue by Region: 2025-2030
3.4 North America Adrenoleukodystrophy Drugs Market Facts & Figures by Country
3.4.1 North America Adrenoleukodystrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Adrenoleukodystrophy Drugs Sales by Country (2019-2030)
3.4.3 North America Adrenoleukodystrophy Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Adrenoleukodystrophy Drugs Market Facts & Figures by Country
3.5.1 Europe Adrenoleukodystrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Adrenoleukodystrophy Drugs Sales by Country (2019-2030)
3.5.3 Europe Adrenoleukodystrophy Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adrenoleukodystrophy Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Adrenoleukodystrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Adrenoleukodystrophy Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Adrenoleukodystrophy Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Adrenoleukodystrophy Drugs Market Facts & Figures by Country
3.7.1 Latin America Adrenoleukodystrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Adrenoleukodystrophy Drugs Sales by Country (2019-2030)
3.7.3 Latin America Adrenoleukodystrophy Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Adrenoleukodystrophy Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Adrenoleukodystrophy Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Adrenoleukodystrophy Drugs Sales by Type (2019-2030)
4.1.1 Global Adrenoleukodystrophy Drugs Sales by Type (2019-2024)
4.1.2 Global Adrenoleukodystrophy Drugs Sales by Type (2025-2030)
4.1.3 Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2019-2030)
4.2 Global Adrenoleukodystrophy Drugs Revenue by Type (2019-2030)
4.2.1 Global Adrenoleukodystrophy Drugs Revenue by Type (2019-2024)
4.2.2 Global Adrenoleukodystrophy Drugs Revenue by Type (2025-2030)
4.2.3 Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Adrenoleukodystrophy Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Adrenoleukodystrophy Drugs Sales by Application (2019-2030)
5.1.1 Global Adrenoleukodystrophy Drugs Sales by Application (2019-2024)
5.1.2 Global Adrenoleukodystrophy Drugs Sales by Application (2025-2030)
5.1.3 Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2019-2030)
5.2 Global Adrenoleukodystrophy Drugs Revenue by Application (2019-2030)
5.2.1 Global Adrenoleukodystrophy Drugs Revenue by Application (2019-2024)
5.2.2 Global Adrenoleukodystrophy Drugs Revenue by Application (2025-2030)
5.2.3 Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Adrenoleukodystrophy Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bluebird Bio Inc
6.1.1 Bluebird Bio Inc Corporation Information
6.1.2 Bluebird Bio Inc Description and Business Overview
6.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Portfolio
6.1.5 Bluebird Bio Inc Recent Developments/Updates
6.2 NeuroVia, Inc.
6.2.1 NeuroVia, Inc. Corporation Information
6.2.2 NeuroVia, Inc. Description and Business Overview
6.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Portfolio
6.2.5 NeuroVia, Inc. Recent Developments/Updates
6.3 Orpheris, Inc.
6.3.1 Orpheris, Inc. Corporation Information
6.3.2 Orpheris, Inc. Description and Business Overview
6.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Orpheris, Inc. Adrenoleukodystrophy Drugs Product Portfolio
6.3.5 Orpheris, Inc. Recent Developments/Updates
6.4 Minoryx
6.4.1 Minoryx Corporation Information
6.4.2 Minoryx Description and Business Overview
6.4.3 Minoryx Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Minoryx Adrenoleukodystrophy Drugs Product Portfolio
6.4.5 Minoryx Recent Developments/Updates
6.5 MedDay Pharmaceuticals
6.5.1 MedDay Pharmaceuticals Corporation Information
6.5.2 MedDay Pharmaceuticals Description and Business Overview
6.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Portfolio
6.5.5 MedDay Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adrenoleukodystrophy Drugs Industry Chain Analysis
7.2 Adrenoleukodystrophy Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adrenoleukodystrophy Drugs Production Mode & Process
7.4 Adrenoleukodystrophy Drugs Sales and Marketing
7.4.1 Adrenoleukodystrophy Drugs Sales Channels
7.4.2 Adrenoleukodystrophy Drugs Distributors
7.5 Adrenoleukodystrophy Drugs Customers
8 Adrenoleukodystrophy Drugs Market Dynamics
8.1 Adrenoleukodystrophy Drugs Industry Trends
8.2 Adrenoleukodystrophy Drugs Market Drivers
8.3 Adrenoleukodystrophy Drugs Market Challenges
8.4 Adrenoleukodystrophy Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
bluebird bio Inc
NeuroVia, Inc.
Orpheris, Inc.
Minoryx
MedDay Pharmaceuticals
List of Tables
    Table 1. Global Adrenoleukodystrophy Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Adrenoleukodystrophy Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Adrenoleukodystrophy Drugs Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Adrenoleukodystrophy Drugs Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Adrenoleukodystrophy Drugs Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Adrenoleukodystrophy Drugs Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Adrenoleukodystrophy Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Adrenoleukodystrophy Drugs, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Adrenoleukodystrophy Drugs, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Adrenoleukodystrophy Drugs, Product Type & Application
    Table 12. Global Key Manufacturers of Adrenoleukodystrophy Drugs, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Adrenoleukodystrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Drugs as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Adrenoleukodystrophy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Adrenoleukodystrophy Drugs Sales by Region (2019-2024) & (K Units)
    Table 18. Global Adrenoleukodystrophy Drugs Sales Market Share by Region (2019-2024)
    Table 19. Global Adrenoleukodystrophy Drugs Sales by Region (2025-2030) & (K Units)
    Table 20. Global Adrenoleukodystrophy Drugs Sales Market Share by Region (2025-2030)
    Table 21. Global Adrenoleukodystrophy Drugs Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region (2019-2024)
    Table 23. Global Adrenoleukodystrophy Drugs Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region (2025-2030)
    Table 25. North America Adrenoleukodystrophy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Adrenoleukodystrophy Drugs Sales by Country (2019-2024) & (K Units)
    Table 27. North America Adrenoleukodystrophy Drugs Sales by Country (2025-2030) & (K Units)
    Table 28. North America Adrenoleukodystrophy Drugs Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Adrenoleukodystrophy Drugs Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Adrenoleukodystrophy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Adrenoleukodystrophy Drugs Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Adrenoleukodystrophy Drugs Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Adrenoleukodystrophy Drugs Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Adrenoleukodystrophy Drugs Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Adrenoleukodystrophy Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Adrenoleukodystrophy Drugs Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Adrenoleukodystrophy Drugs Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Adrenoleukodystrophy Drugs Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Adrenoleukodystrophy Drugs Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Adrenoleukodystrophy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Adrenoleukodystrophy Drugs Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Adrenoleukodystrophy Drugs Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Adrenoleukodystrophy Drugs Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Adrenoleukodystrophy Drugs Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Adrenoleukodystrophy Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Adrenoleukodystrophy Drugs Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Adrenoleukodystrophy Drugs Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Adrenoleukodystrophy Drugs Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Adrenoleukodystrophy Drugs Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Adrenoleukodystrophy Drugs Sales (K Units) by Type (2019-2024)
    Table 51. Global Adrenoleukodystrophy Drugs Sales (K Units) by Type (2025-2030)
    Table 52. Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2019-2024)
    Table 53. Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2025-2030)
    Table 54. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2019-2024)
    Table 57. Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2025-2030)
    Table 58. Global Adrenoleukodystrophy Drugs Price (US$/Unit) by Type (2019-2024)
    Table 59. Global Adrenoleukodystrophy Drugs Price (US$/Unit) by Type (2025-2030)
    Table 60. Global Adrenoleukodystrophy Drugs Sales (K Units) by Application (2019-2024)
    Table 61. Global Adrenoleukodystrophy Drugs Sales (K Units) by Application (2025-2030)
    Table 62. Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2019-2024)
    Table 63. Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2025-2030)
    Table 64. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2019-2024)
    Table 67. Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2025-2030)
    Table 68. Global Adrenoleukodystrophy Drugs Price (US$/Unit) by Application (2019-2024)
    Table 69. Global Adrenoleukodystrophy Drugs Price (US$/Unit) by Application (2025-2030)
    Table 70. Bluebird Bio Inc Corporation Information
    Table 71. Bluebird Bio Inc Description and Business Overview
    Table 72. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 73. Bluebird Bio Inc Adrenoleukodystrophy Drugs Product
    Table 74. Bluebird Bio Inc Recent Developments/Updates
    Table 75. NeuroVia, Inc. Corporation Information
    Table 76. NeuroVia, Inc. Description and Business Overview
    Table 77. NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 78. NeuroVia, Inc. Adrenoleukodystrophy Drugs Product
    Table 79. NeuroVia, Inc. Recent Developments/Updates
    Table 80. Orpheris, Inc. Corporation Information
    Table 81. Orpheris, Inc. Description and Business Overview
    Table 82. Orpheris, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 83. Orpheris, Inc. Adrenoleukodystrophy Drugs Product
    Table 84. Orpheris, Inc. Recent Developments/Updates
    Table 85. Minoryx Corporation Information
    Table 86. Minoryx Description and Business Overview
    Table 87. Minoryx Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 88. Minoryx Adrenoleukodystrophy Drugs Product
    Table 89. Minoryx Recent Developments/Updates
    Table 90. MedDay Pharmaceuticals Corporation Information
    Table 91. MedDay Pharmaceuticals Description and Business Overview
    Table 92. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 93. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product
    Table 94. MedDay Pharmaceuticals Recent Developments/Updates
    Table 95. Key Raw Materials Lists
    Table 96. Raw Materials Key Suppliers Lists
    Table 97. Adrenoleukodystrophy Drugs Distributors List
    Table 98. Adrenoleukodystrophy Drugs Customers List
    Table 99. Adrenoleukodystrophy Drugs Market Trends
    Table 100. Adrenoleukodystrophy Drugs Market Drivers
    Table 101. Adrenoleukodystrophy Drugs Market Challenges
    Table 102. Adrenoleukodystrophy Drugs Market Restraints
    Table 103. Research Programs/Design for This Report
    Table 104. Key Data Information from Secondary Sources
    Table 105. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Adrenoleukodystrophy Drugs
    Figure 2. Global Adrenoleukodystrophy Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Adrenoleukodystrophy Drugs Market Share by Type in 2023 & 2030
    Figure 4. Hormone Replacement Product Picture
    Figure 5. Transplant Product Picture
    Figure 6. Others Product Picture
    Figure 7. Global Adrenoleukodystrophy Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 8. Global Adrenoleukodystrophy Drugs Market Share by Application in 2023 & 2030
    Figure 9. Childhood Cerebral ALD
    Figure 10. Adrenomyeloneuropathy (AMN)
    Figure 11. Addison-only
    Figure 12. Others
    Figure 13. Global Adrenoleukodystrophy Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Adrenoleukodystrophy Drugs Market Size (2019-2030) & (US$ Million)
    Figure 15. Global Adrenoleukodystrophy Drugs Sales (2019-2030) & (K Units)
    Figure 16. Global Adrenoleukodystrophy Drugs Average Price (US$/Unit) & (2019-2030)
    Figure 17. Adrenoleukodystrophy Drugs Report Years Considered
    Figure 18. Adrenoleukodystrophy Drugs Sales Share by Manufacturers in 2023
    Figure 19. Global Adrenoleukodystrophy Drugs Revenue Share by Manufacturers in 2023
    Figure 20. The Global 5 and 10 Largest Adrenoleukodystrophy Drugs Players: Market Share by Revenue in 2023
    Figure 21. Adrenoleukodystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 22. Global Adrenoleukodystrophy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 23. North America Adrenoleukodystrophy Drugs Sales Market Share by Country (2019-2030)
    Figure 24. North America Adrenoleukodystrophy Drugs Revenue Market Share by Country (2019-2030)
    Figure 25. U.S. Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 26. Canada Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 27. Europe Adrenoleukodystrophy Drugs Sales Market Share by Country (2019-2030)
    Figure 28. Europe Adrenoleukodystrophy Drugs Revenue Market Share by Country (2019-2030)
    Figure 29. Germany Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. France Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. U.K. Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Italy Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. Russia Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 34. Asia Pacific Adrenoleukodystrophy Drugs Sales Market Share by Region (2019-2030)
    Figure 35. Asia Pacific Adrenoleukodystrophy Drugs Revenue Market Share by Region (2019-2030)
    Figure 36. China Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. Japan Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. South Korea Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. India Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Australia Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. Taiwan Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Indonesia Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Thailand Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Malaysia Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Philippines Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 46. Latin America Adrenoleukodystrophy Drugs Sales Market Share by Country (2019-2030)
    Figure 47. Latin America Adrenoleukodystrophy Drugs Revenue Market Share by Country (2019-2030)
    Figure 48. Mexico Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Brazil Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 50. Argentina Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 51. Middle East & Africa Adrenoleukodystrophy Drugs Sales Market Share by Country (2019-2030)
    Figure 52. Middle East & Africa Adrenoleukodystrophy Drugs Revenue Market Share by Country (2019-2030)
    Figure 53. Turkey Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 54. Saudi Arabia Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 55. UAE Adrenoleukodystrophy Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 56. Global Sales Market Share of Adrenoleukodystrophy Drugs by Type (2019-2030)
    Figure 57. Global Revenue Market Share of Adrenoleukodystrophy Drugs by Type (2019-2030)
    Figure 58. Global Adrenoleukodystrophy Drugs Price (US$/Unit) by Type (2019-2030)
    Figure 59. Global Sales Market Share of Adrenoleukodystrophy Drugs by Application (2019-2030)
    Figure 60. Global Revenue Market Share of Adrenoleukodystrophy Drugs by Application (2019-2030)
    Figure 61. Global Adrenoleukodystrophy Drugs Price (US$/Unit) by Application (2019-2030)
    Figure 62. Adrenoleukodystrophy Drugs Value Chain
    Figure 63. Adrenoleukodystrophy Drugs Production Process
    Figure 64. Channels of Distribution (Direct Vs Distribution)
    Figure 65. Distributors Profiles
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Cystic Fibrosis (Mucoviscoidosis) Testing Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-24R5886
Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Congenital Heart Diseases Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-29D6035
Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Gardner Syndrome Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-28H13051
Tue Mar 26 00:00:00 UTC 2024

Add to Cart

Drugs for Alport Syndrome - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-16A13427
Tue Mar 26 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions